ATE293691T1 - Myostatin genpromoter und inhibierung dessen aktivierung - Google Patents

Myostatin genpromoter und inhibierung dessen aktivierung

Info

Publication number
ATE293691T1
ATE293691T1 AT00941296T AT00941296T ATE293691T1 AT E293691 T1 ATE293691 T1 AT E293691T1 AT 00941296 T AT00941296 T AT 00941296T AT 00941296 T AT00941296 T AT 00941296T AT E293691 T1 ATE293691 T1 AT E293691T1
Authority
AT
Austria
Prior art keywords
inhibition
activation
myostatin
gene promoter
myostatin gene
Prior art date
Application number
AT00941296T
Other languages
English (en)
Inventor
Jinshyun R Wu-Wong
Jiahong Wang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE293691T1 publication Critical patent/ATE293691T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00941296T 1999-06-10 2000-06-09 Myostatin genpromoter und inhibierung dessen aktivierung ATE293691T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/329,685 US6284882B1 (en) 1999-06-10 1999-06-10 Myostatin gene promoter and inhibition of activation thereof
PCT/US2000/015868 WO2000077206A2 (en) 1999-06-10 2000-06-09 The myostatin gene promoter and inhibition of activation thereof

Publications (1)

Publication Number Publication Date
ATE293691T1 true ATE293691T1 (de) 2005-05-15

Family

ID=23286552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941296T ATE293691T1 (de) 1999-06-10 2000-06-09 Myostatin genpromoter und inhibierung dessen aktivierung

Country Status (10)

Country Link
US (2) US6284882B1 (de)
EP (1) EP1185649B1 (de)
JP (1) JP4625602B2 (de)
AT (1) ATE293691T1 (de)
CA (1) CA2375820C (de)
DE (1) DE60019586T2 (de)
ES (1) ES2240108T3 (de)
MX (1) MXPA01012665A (de)
PT (1) PT1185649E (de)
WO (1) WO2000077206A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1097233T3 (da) * 1998-07-15 2009-03-23 Metamorphix Inc Promotor for vækstdifferentieringsfaktor og anvendelser deraf
ZA200003786B (en) * 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.
DE60228710D1 (en) * 2001-07-11 2008-10-16 Ovita Ltd Bioassay für myostatin
EP2272864A3 (de) * 2002-12-20 2011-02-16 Amgen Inc. Bindende Wirkstoffe zum Hemmen von Myostatin
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
CA2514184C (en) 2003-01-21 2016-04-12 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
EP1699820A2 (de) * 2003-12-31 2006-09-13 Schering-Plough Ltd. Wachstumsfördernder impfstoff auf basis des neutralisierenden epitops
US20060130157A1 (en) 2004-10-22 2006-06-15 Kevin Wells Ungulates with genetically modified immune systems
TW200634156A (en) * 2004-12-30 2006-10-01 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine
EP1855694B1 (de) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense-zusammensetzung zur behandlung von muskelatrophie
WO2006102574A2 (en) * 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
US20060240488A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of an immune response to GDF-8 modulating agents
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
AU2006321906C1 (en) * 2005-12-06 2014-01-16 Amgen Inc. Uses of myostatin antagonists
US8426374B1 (en) 2006-05-04 2013-04-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Method for modifying myostatin expression
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
BRPI0817233A2 (pt) 2007-09-28 2012-11-06 Intrexon Corp construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
BR112018007066A2 (pt) 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690873B1 (de) * 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Wachstumsfaktor-8
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
AU6274298A (en) * 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
DK1097233T3 (da) * 1998-07-15 2009-03-23 Metamorphix Inc Promotor for vækstdifferentieringsfaktor og anvendelser deraf
ZA200003786B (en) 1999-07-30 2002-01-21 Pfizer Prod Inc Myostatin regulatory region, nucleotide sequence determination and methods for its use.

Also Published As

Publication number Publication date
US6399312B2 (en) 2002-06-04
US20010049435A1 (en) 2001-12-06
JP2003528574A (ja) 2003-09-30
ES2240108T3 (es) 2005-10-16
WO2000077206A3 (en) 2001-12-06
DE60019586T2 (de) 2006-03-09
DE60019586D1 (de) 2005-05-25
EP1185649A2 (de) 2002-03-13
WO2000077206A2 (en) 2000-12-21
CA2375820C (en) 2010-07-27
PT1185649E (pt) 2005-08-31
CA2375820A1 (en) 2000-12-21
US6284882B1 (en) 2001-09-04
EP1185649B1 (de) 2005-04-20
MXPA01012665A (es) 2002-07-22
JP4625602B2 (ja) 2011-02-02

Similar Documents

Publication Publication Date Title
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
BG106020A (en) Inhibitors of impdh enzyme
AU3652102A (en) Compounds and their uses
PL402389A1 (pl) Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat
PT966465E (pt) Inibidores do enzima imfdh
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MY142915A (en) Rho-kinase inhibitors
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
DK1200418T3 (da) Nematodicide trifluorbutener
GEP20084488B (en) Use of therapeutic agents for treating pain
DE60324544D1 (de) Muskarin antagonisten
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
EP1244452A4 (de) Urotensin-ii rezeptorantagonisten
BG105710A (en) 5ht1 antagonists for antidepressant therapy
ATE443044T1 (de) Tace inhibitoren
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EA200100930A1 (ru) Способ лечения хозл
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1185649

Country of ref document: EP

REN Ceased due to non-payment of the annual fee